Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL20549067 | 0.96 | — | — | |
| Ethane SCHEMBL8942634 | 0.84 | ALDH1A1 (0.73) | ALDH1A1TTRTSHR | |
| SCHEMBL2846103 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| Tetrahydrofuran SCHEMBL11026489 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| SCHEMBL10713952 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| SCHEMBL2845030 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| SCHEMBL2848269 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| SCHEMBL87670 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| SCHEMBL5386353 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR | |
| SCHEMBL4788259 | 0.83 | ALDH1A1 (0.89) | ALDH1A1TTRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595951-B1 | A PROCESS FOR THE PRODUCTION OF CARNITINE | LONZA AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-8563752-B2 | Process for the production of carnitine by cycloaddition | LONZA LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2595951-A1 | A PROCESS FOR THE PRODUCTION OF CARNITINE | Lonza Ltd. (CH) | 2013-05-29 | — | — | EP | disclosed |
| CN-102971285-A | A process for the production of carnitine | LONZA AG | 2013-03-13 | — | — | CN | disclosed |
| US-20120022275-A1 | PROCESS FOR THE PRODUCTION OF CARNITINE BY CYCLOADDITION | LONZA LTD. (CH) | 2012-01-26 | — | — | US | disclosed |
| WO-2012010296-A1 | A PROCESS FOR THE PRODUCTION OF CARNITINE | LONZA LTD (CH) | 2012-01-26 | — | — | WO | disclosed |
| EP-2409965-A1 | A process for the production of carnitine by cycloaddition | Lonza Ltd. (CH) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022275-A1 | PROCESS FOR THE PRODUCTION OF CARNITINE BY CYCLOADDITION | CRAT, CPT2, CPT1B | ALDH1A1 832/4885TTR 2522/4885TSHR 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.